Advertisement

Botulinum Toxin

  • Thomas Muehlberger
Chapter

Abstract

The use of botulinum toxin as a treatment for migraine has an inconsistent and lingering history. Following years of rejection, the PREEMPT trials eventually found that it is useful as a prophylactic for chronic migraines. The surgical and neurological approaches employing botulinum, however, are fundamentally different. Furthermore, the surgical use is based on its peripheral mechanism, a localized muscle paralysis, whereas the neurological use is based on alleged central mechanisms and directly antinociceptive properties. The botulinum-induced deactivation of trigger sites can simulate the surgical procedure and should be used as a preoperative test. There is no standardized method to determine the individual selection of trigger sites; the approach presented herewith is a recommendation. Botulinum toxin is a safe and effective agent with rare, mild, and transient side effects.

References

  1. 1.
    Kerner J. Poisoning from rotten sausages (Article in German). Tubinger Blätter für Naturwissenschaften und Arzneykunde. 1817;3:1–25.Google Scholar
  2. 2.
    Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115:559–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Investig Ophthalmol. 1973;12:924–7.Google Scholar
  4. 4.
    Knize DM. Discussion. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112:174S–6S.CrossRefGoogle Scholar
  5. 5.
    Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Gupta S. How to prevent a migraine. TIME. 2002;1Google Scholar
  7. 7.
    Binder WJ, Brin MF, Blitzer A, Schoenrock LB, Pagoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123:669–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment for the BOTOX Migraine Clinical Research Group. Headache. 2000;40:445–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Göbel H, Heinze A, Heinze-Kuhn K, Jost WH. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol. 2001;248:S34–8.CrossRefGoogle Scholar
  10. 10.
    Obermann M, Diener HC. Is botulinum toxin useful in treating headache? No. Curr Treat Options Neurol. 2009;11:24–31.CrossRefPubMedGoogle Scholar
  11. 11.
    Pakalnis A, Couch J. Headache therapy with botulinum toxin: form over substance. Arch Neurol. 2008;65:149–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Roach ES. Questioning botulinum toxin for headache: reality or illusion. Arch Neurol. 2008;65:151–2.PubMedGoogle Scholar
  13. 13.
    Solomon S. Botulinum toxin for the treatment of chronic migraine: the placebo effect. Headache. 2011;51:980–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol. 2008;65:146–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Becker D, Amirlak B. Beyond beauty: onobotulinumtoxin A (BOTOX®) and the management of migraine headaches. Anesth Pain Med. 2012;2:5–11.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nahabet E, Janis JE, Guyuron B. Neurotoxins: expanding uses of neuromodulators in medicine—headache. Plast Reconstr Surg. 2015;136:104S–10S.CrossRefPubMedGoogle Scholar
  17. 17.
    Behmand RA, Tucker T, Guyuron B. Single-site botulinum toxin type A injection for elimination of migraine trigger points. Headache. 2003;43:1085–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112(S5):171S–3S.CrossRefPubMedGoogle Scholar
  19. 19.
    Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: single-surgeon experience using botulinum toxin and surgical decompression. Plast Reconstr Surg. 2011;128:123–31.CrossRefPubMedGoogle Scholar
  20. 20.
    de Ru JA. Botulinum toxin-A is an effective and safe treatment for chronic migraine. Headache. 2013;53(7):1165.CrossRefPubMedGoogle Scholar
  21. 21.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47:486–99.CrossRefPubMedGoogle Scholar
  22. 22.
    Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain. 2003;4:146–51.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Chilson CN, Brown SJ. Role of botulinum toxin type A in the prophylactic treatment of migraine headaches. Ann Pharmacother. 2005;39:2081–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol. 2008;10:20–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307:1736–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain. 2006;125:286–95.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon. 2009;54:624–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kim CC, Bogart MM, Wee SA, Burstein R, Arndt KA, Dover JS. Predicting migraine responsiveness to botulinum toxin type A injections. Arch Dermatol. 2010;146:59–63.Google Scholar
  29. 29.
    Kosaras B, Jakubowski M, Kainz V, Burstein R. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol. 2009;515:331–48.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Saers SJ, de Ru JA. Botulinum toxin type A headache treatment and entrapment of the supratrochlear nerve. Arch Dermatol. 2010;146:1310–1; author reply 1311.CrossRefPubMedGoogle Scholar
  31. 31.
    Files JA, Schwedt TJ, Mayer AP, David PS, Vargas BB, Chang YH, Hunt M, Patel S, Ko MG, Tozer BS, Burstein R, Dodick DW. Imploding and exploding migraine headaches: comparison of methods to diagnose pain directionality. Headache. 2014;54:1010–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Goadsby P. Squeezing life into botulinum toxin A in migraine: imploding vs exploding pain. Pain. 2006;125:206–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Blumenfeld A, Silberstein SD, Dodick DW, et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.CrossRefPubMedGoogle Scholar
  34. 34.
    Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.CrossRefPubMedGoogle Scholar
  35. 35.
    Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.CrossRefPubMedGoogle Scholar
  36. 36.
    Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51:1358–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.CrossRefPubMedGoogle Scholar
  38. 38.
    Matharu M, Halker R, Pozo-Rosich P, et al. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain. 2017;18:78.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Rothrock JF. Botox-A for suppression of chronic migraine: commonly asked questions. Headache. 2012;52:716–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Delstanche S, Schoenen J. Botulinum toxin for the treatment of headache: a promising path on a “dead end road”? Acta Neurol Belg. 2010;110:221–9.PubMedGoogle Scholar
  41. 41.
    Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet. 2010;376:1825–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Finkel AG. Botulinum toxin and the treatment of headache: a clinical review. Headache. 2011;51:1565–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Rothrock JF. OnabotulinumtoxinA for the treatment of chronic migraine. Headache. 2011;51:659–60.CrossRefPubMedGoogle Scholar
  44. 44.
    Rothrock JF. Let’s give Botox a break. Headache. 2012;52:1204–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Boes CJ, Capobianco DJ. Chronic migraine and medication-overuse headache through the ages. Cephalalgia. 2005;25:378–90.CrossRefPubMedGoogle Scholar
  46. 46.
    Rothrock JF. Treatment-refractory chronic migraine: the ogre emerges from the shadows. Headache. 2009;49:631–3.CrossRefPubMedGoogle Scholar
  47. 47.
    Olesen J. Problem areas in the International Classification of Headache Disorders, 3rd edition (beta). Cephalalgia. 2014;34:1193–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26(6):742.CrossRefPubMedGoogle Scholar
  49. 49.
    Ahmed F, Zafar HW, Buture A, Khalil M. Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus. 2015;4:589.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251(S1):1–7.CrossRefGoogle Scholar
  51. 51.
    Caleo M, Antonucci F, Restani L, et al. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem. 2009;109:15–24.CrossRefPubMedGoogle Scholar
  52. 52.
    Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins (Basel). 2010;2:2890–13.CrossRefGoogle Scholar
  53. 53.
    Pavone F, Ueda H. Is BoNT/B useful for pain treatment? Pain. 2014;155:649–50.CrossRefPubMedGoogle Scholar
  54. 54.
    Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol. 2014;171:4177–92.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–93.CrossRefPubMedGoogle Scholar
  56. 56.
    Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17:S28–33.CrossRefPubMedGoogle Scholar
  57. 57.
    Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Gazerani P, Au S, Dong X, Kumar U, Arendt-Nielsen L, Cairns BE. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain. 2010;151:606–16.CrossRefPubMedGoogle Scholar
  59. 59.
    Shimizu T, Shibata M, Toriumi H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis. 2012;48:367–78.CrossRefPubMedGoogle Scholar
  60. 60.
    Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34:853–69.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Zhang X, Strassman AM, Novack V, Brin MF, Burstein R. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia. 2016;36:875–86.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Filipović B, Matak I, Bach-Rojecky L, Lacković Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One. 2012;7:e29803.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain. 2007;130:76–83.CrossRefPubMedGoogle Scholar
  64. 64.
    Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18:S125–32.CrossRefPubMedGoogle Scholar
  65. 65.
    Robertson CE, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr Dis Treat. 2012;8:35–48.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124–46.CrossRefPubMedGoogle Scholar
  67. 67.
    Matak I, Lacković Z. Botulinum toxin A, brain and pain. Prog Neurobiol. 2014;119–120:39–59.CrossRefPubMedGoogle Scholar
  68. 68.
    de Ru J. More comments on migraine trigger site decompression surgery: focus on frontal headache. Headache. 2015;55:702–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Mathew P. A critical evaluation of migraine trigger site deactivation surgery. Headache. 2014;54:142–52.CrossRefPubMedGoogle Scholar
  70. 70.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache. 2005;45:308–14.CrossRefPubMedGoogle Scholar
  71. 71.
    Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012;129:413–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Seyed Forootan NS, Lee M, Guyuron B. Migraine headache trigger site prevalence analysis of 2590 sites in 1010 patients. J Plast Reconstr Aesthet Surg. 2017;70:152–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Janis JE, Barker JC, Palettas M. Targeted peripheral nerve-directed onabotulinumtoxin A injection for effective long-term therapy for migraine headache. Plast Reconstr Surg Glob Open. 2017;5:e1270.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Amirlak B, Sanniec K, Pezeshk R, Chung M. Anatomical regional targeted (ART) BOTOX injection technique: a novel paradigm for migraines and chronic headaches. Plast Reconstr Surg Glob Open. 2016;4:e1194.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    de Ru JA, Buwalda J. Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache. J Laryngol Otol. 2009;123:412–7.CrossRefPubMedGoogle Scholar
  76. 76.
    Lee M, Monson MA, Liu MT, Reed D, Guyuron B. Positive botulinum toxin type A response is a prognosticator for migraine surgery success. Plast Reconstr Surg. 2013;131:751–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Ascha M, Kurlander DE, Sattar A, Gatherwright J, Guyuron B. In-depth review of symptoms, triggers, and treatment of occipital migraine headaches (site IV). Plast Reconstr Surg. 2017;139:1333e–42e.CrossRefPubMedGoogle Scholar
  78. 78.
    Kurlander DE, Punjabi A, Liu MT, Sattar A, Guyuron B. In-depth review of symptoms, triggers, and treatment of temporal migraine headaches (Site II). Plast Reconstr Surg. 2014;133:897–903.CrossRefPubMedGoogle Scholar
  79. 79.
    Cohen JL, Scuderi N. Safety and patient satisfaction of Abobotulinumtoxin A for aesthetic use: a systematic review. Aesthet Surg J. 2017;37:S32–44.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Redaelli A, Forte R. How to avoid brow ptosis after forehead treatment with botulinum toxin. J Cosmet Laser Ther. 2003;5:220–2.CrossRefPubMedGoogle Scholar
  81. 81.
    Cho ES, Hwang JY, Kim ST. A proposal to prevent the “Mephisto sign” side effect of botulinum toxin type A injection in chronic migraine. Yonsei Med J. 2013;54:1542–4.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Russo A, Silvestro M, Tessitore A, Tedeschi G. The “ram’s horns sign”: a case report of an unusual side effect of OnabotulinumtoxinA in a chronic migraine patient. Headache. 2016;56:1656–8.CrossRefPubMedGoogle Scholar
  83. 83.
    Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994;9:31–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Omoigui S, Irene S. Treatment of ptosis as a complication of botulinum toxin injection. Pain Med. 2005;6:149–51.CrossRefPubMedGoogle Scholar
  85. 85.
    Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatol Online J. 2005;11:9.PubMedGoogle Scholar
  86. 86.
    Steinsapir KD, Groth MJ, Boxrud CA. Persistence of upper blepharoptosis after cosmetic botulinum toxin type A. Dermatol Surg. 2015;41:833–40.CrossRefPubMedGoogle Scholar
  87. 87.
    Guyuron B, Rose K, Kriegler JS, Tucker T. Hourglass deformity after botulinum toxin type A injection. Headache. 2004;44:262–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Thomas Muehlberger
    • 1
  1. 1.Medsteps AGChamSwitzerland

Personalised recommendations